Expansion Strategy for EBV-Associated Nasopharyngeal Carcinoma

Baizencell is seeking to enter the Chinese market with its EBV (Epstein-Barr Virus)-targeted immune cell therapy, 'VT-EBV-N'.

<image alt="Baizencell company logo image">Baizencell</image>

Baizencell company logo imageBaizencell

View original image

On March 10, Baizencell announced that it will participate in "BioChina 2026," a bioindustry event held in Suzhou, China from March 12 to 14, where it plans to discuss technology licensing with global and Chinese pharmaceutical companies.


The company's core pipeline, VT-EBV-N, demonstrated therapeutic efficacy in a randomized, double-blind Phase 2 clinical trial targeting NK/T-cell lymphoma. The 2-year disease-free survival (DFS) rate for the treatment group was 95.0%, higher than the 77.58% observed in the control group. According to the company, all patients in the treatment group survived.


VT-EBV-N is an immune cell therapy that targets EBV. It is also being evaluated for its potential to expand indications beyond NK/T-cell lymphoma to include solid tumors associated with EBV, such as nasopharyngeal carcinoma.


Baizencell views the large patient population in the Chinese market as a business opportunity. According to the company, the number of NK/T-cell lymphoma patients in China is about 30 times greater than in Korea. When including nasopharyngeal carcinoma, an EBV-mediated solid tumor, the number of new patients is estimated at approximately 60,000 per year.


The company plans to seek technology licensing partners among local pharmaceutical firms in China that have capabilities in regulatory compliance, manufacturing infrastructure, and distribution networks. In addition to the size of the contract, Baizencell aims to establish a collaborative structure that covers approval and sales, with the goal of securing long-term revenue and royalties.



This business development initiative is being led by Sunyoung Kim, Executive Director of Global Business Development (BD), who recently joined the company. At the event, Baizencell also plans to introduce its preclinical glioblastoma pipeline 'VC302' and its own GMP manufacturing facility.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing